Nonalcoholic fatty liver disease among HIV-infected persons

Journal of Acquired Immune Deficiency Syndromes

Volumn 50, Issue 5, 2009, Pages 464-473

  Crum Cianflone, Nancy ^a,b,c   Dilay, Angelica ^c   Collins, Gary ^d   Asher, Dean ^a   Campin, Richard ^a   Medina, Sheila ^a,b   Goodman, Zach ^e   Parker, Robin ^a   Lifson, Alan ^d   Capozza, Thomas ^a   Bavaro, Mary ^a   Hale, Braden ^a,b   Hames, Charles ^a  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAN DIEGO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

Antiretroviral medication; HIV; Liver disease; NAFLD; Steatosis

Indexed keywords

ANTIRETROVIRUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MIXED INFECTION; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RISK FACTOR; ULTRASOUND; VIRUS LOAD; WAIST CIRCUMFERENCE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; ECHOGRAPHY; FATTY LIVER; MIDDLE AGED; PREVALENCE;

ADULT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS;

EID: 65449180351     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318198a88a     Document Type: Article

References (53)

1. Palella FJ Jr, Baker RK, Moorman AC, et al; HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIVoutpatient study. J Acquir Immune Defic Syndr. 2006;43:27-34.
2. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
3. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficieny virus: the D:A:D study. Arch Intern Med. 2006;166:1632-1641.
4. Pol S, Lebray P, Vallet-Pichard A. HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Clin Infect Dis. 2004;38:S65-S72.
5. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438.
6. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113-121.
7. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99-S112.
8. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37: 1202-1219.
9. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1705-1725.
10. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006;40:S17-S29.
11. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-1419.
12. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
13. Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002;35:367-372.
14. Poles MA, Dieterich DT, Schwarz ED, et al. Liver biopsy findings in 501 patients infected with human immunodeficiency virus (HIV). J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11:170-177.
15. Grumbach K, Coleman BG, Gal AA, et al. Hepatic and biliary tract abnormalities in patients with AIDS. Sonographic-pathologic correlation. J Ultrasound Med. 1989;8:247-254.
16. Beale TJ, Wetton CW, Crofton ME. A sonographic-pathological correlation of liver biopsies in patients with the acquired immunodeficiency syndrome (AIDS). Clin Radiol. 1995;50:761-764.
17. Trojan A, Kreuzer KA, Flury R, et al. Liver changes in AIDS. Retrospective analysis of 227 autopsies of HIV-positive patients. Pathologe. 1998;19:194-200.
18. Neau D, Winnock M, Castéra L, et al; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine Cohort. J Acquir Immune Defic Syndr. 2007;45: 168-173.
19. Marks KM, Petrovic LM, Talal AH, et al. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C. J Infect Dis. 2005;192:1943-1949.
20. Bani-Sadr F, Carrat F, Bedossa P, et al; ANRS HC02-Ribavic Study Team. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS. 2006;20:525-531.
21. Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol. 2006;44:1026-1032.
22. McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis. 2006; 43:365-372.
23. Monto A, Dove LM, Bostrom A, et al. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Hepatology. 2005;42:310-316.
24. Sulkowski MS, Mehta SH, Torbenson M, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS. 2005;19:585-592.
25. Zeremiski M, Talal AH. Dideoxynucleoside analogues should be used cautiously in patients with hepatic steatosis. Clin Infect Dis. 2006;43:373-376.
26. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998;114:842-884.
27. Riddle TM, Kuhel DG, Woollett LA, et al. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element binding proteins in the nucleus. J Biol Chem. 2001;275:37514-37519.
28. Lemoine M, Barbu V, Girard PM, et al. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS. 2006;20:387-395.
29. Amorosa V, Synnestvedt M, Gross R, et al. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr. 2005;39:557-561.
30. Brown TT, Li X, Cole SR, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165:1179-1184.
31. Wigg AJ, Roberts-Thomson IC, Dymock RB, et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut. 2001;48:206-211.
32. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - The evidence report. National Institutes of Health. Obes Res. 1998;6:51S-209S.
33. Rumack CM, Wilson S, Charboneau WJ, et al. Diagnostic Ultrasound. Vol 1. 3rd ed. St Louis, MO: Elsevier Mosby; 2005.
34. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699.
35. Loulergue P, Callard P, Bonnard P, et al. Hepatic steatosis as an emerging cause of cirrhosis in HIV-infected patients. J Acquir Immune Defic Syndr. 2007;45:365.
36. Arslan U, Türkoǧlu S, Balcioǧlu S, et al. Association between nonalcoholic fatty liver disease and coronary artery disease. Coron Artery Dis. 2007;18:433-436.
37. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44: 865-873.
38. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr. 2004;79: 379-384.
39. Eguchi Y, Eguchi T, Mizuta T, et al. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J Gastroenterol. 2006;41:462-469.
40. Machado M, Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care. 2006;9:637-642.
41. Diehl AM, Li ZP, Lin HZ, et al. Cytokines and the pathogenesis of nonalchoholic steatohepatitis. Gut. 2005;54:303-306.
42. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143: 722-728.
43. Jacobson DL, Tang AM, Spiegelman D, et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr. 2006;43:458-466.
44. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395.
45. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295:1549-1555.
46. Albisetti M, Braegger CP, Stallmach T, et al. Hepatic steatosis: a frequent non-specific finding in HIV-infected children. Eur J Pediatr. 1999;158: 971-974.
47. Bäuerle J, Miquel R, Laguno M, et al. Hepatic steatosis with stavudine in HIV/hepatitis C co-infection [letter]. AIDS. 2005;19:1441-1442.
48. Castéra L, Loko MA, Le Bail B, et al; Groupe D'epidé miologie Clinique du Sida en Aquitaine (GECSA). Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype. Aliment Pharmacol Ther. 2007; 26:1489-1498.
49. Yamanaka H, Gatanaga H, Kosalaraksa P, et al. Novel mutation of human DNA polymerase gamma associated with mitochondrial toxicity induced by anti-HIV treatment. J Infect Dis. 2007;195:1419-1425.
50. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1-9.
51. Frieman JP, Helfert KE, Hamrell MR, et al. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS. 1993;7:379-385.
52. Joseph AE, Savery muttu SH, al-Sam S, et al. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol. 1991;43:26-31.
53. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123: 745-750.